Novartis and Celgene get EU approval for novel psoriasis therapies

 
• By Alexandra Shimmings

The European Commission has approved two new drugs for psoriasis: Novartis's Cosentyx (secukinumab) and Celgene's Otezla (apremilast).

More from Dermatological

More from Therapy Areas